ERBB2 and breast carcinoma: HER2 has long been known to be amplified and overexpressed in breast [66], gastric [67], and bladder cancers [68] and large scale copy number analysis confirms that HER2 is amplified most frequently in gastric followed by breast cancer (Figure 3A).